Physician profile
David K Spady
NPI 1639155005
$9,956.84
in general payments reported to CMS, 2019-2025
43 companies · $1,748 in 2025
The $1,748 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,858 · 2020: $409 · 2021: $792 · 2022: $1,774 · 2023: $1,499 · 2024: $1,876 · 2025: $1,748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,995 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,994.96 |
| Education | $128.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,608.55 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Scientific Affairs, LLC | $1,537.59 | 2019-2025 | Remicade, Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $669.47 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $655.35 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $615.64 | 2019-2025 | Entyvio |
| Pfizer INC. | $410.87 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $328.57 | 2019-2024 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $289.27 | 2021-2024 | Zeposia |
| Genzyme Corporation | $276.56 | 2022-2025 | |
| Lilly USA, LLC | $196.89 | 2023-2024 | Omvoh |
| Ethicon US, LLC | $193.24 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $187.76 | 2023-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $184.16 | 2019-2024 | Dificid |
| Madrigal Pharmaceuticals | $137.85 | 2025 | Rezdiffra |
| Johnson & Johnson Health Care Systems INC. | $129.02 | 2024 | Stelara |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $128.69 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $126.35 | 2019-2025 | Rebyota |
| Daiichi Sankyo INC. | $123.81 | 2019-2023 | Injectafer |
| Enterra Medical, INC. | $96.34 | 2025 | |
| Qol Medical, LLC | $85.35 | 2019-2022 | |
| Organon LLC | $84.77 | 2021-2024 | |
| Covidien LP | $77.00 | 2019 | |
| Allergan, INC. | $69.99 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $67.55 | 2024-2025 | Zenpep, Vowst |
| Amgen INC. | $61.66 | 2021-2022 | |
| Celltrion USA INC. | $59.70 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
| Braintree Laboratories, INC. | $55.67 | 2022-2024 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $50.90 | 2024-2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $49.32 | 2023-2024 | Idacio |
| Mauna Kea Technologies, INC. | $49.15 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $47.96 | 2023-2025 | Dupixent |
| Ardelyx, INC. | $47.30 | 2022-2025 | Ibsrela |
| Celgene Corporation | $44.79 | 2022-2023 | Zeposia |
| Vivus LLC | $36.92 | 2025 | Pancreaze |
| Alfasigma USA, INC. | $32.61 | 2020 | |
| Nestle Healthcare Nutrition INC. | $30.52 | 2022-2023 | |
| Redhill Biopharma INC. | $25.33 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Gilead Sciences, INC. | $20.16 | 2019 | |
| Perspectum Diagnostics LTD | $16.83 | 2022 | |
| Evoke Pharma, INC. | $16.65 | 2025 | |
| Ucb, INC. | $16.28 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $14.45 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Spady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.